| Momelotinib (CYT387) |
NCT00935987 |
Completed |
Phase 1|Phase 2 |
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00935987 |
| Momelotinib (CYT387) |
NCT01236638 |
Completed |
Phase 2 |
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01236638 |
| Momelotinib (CYT387) |
NCT01423058 |
Completed |
Phase 1|Phase 2 |
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis |
Primary Myelofibrosis|Post-Polycythemia Vera|Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01423058 |
| Momelotinib (CYT387) |
NCT03441113 |
Enrolling by invitation |
Phase 2 |
Extended Access of Momelotinib in Adults With Myelofibrosis |
Post-polycythemia Vera Myelofibrosis (Post-PV MF)|Primary Myelofibrosis (PMF)|Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) |
https://ClinicalTrials.gov/show/NCT03441113 |
| Momelotinib (CYT387) |
NCT02515630 |
Completed |
Phase 2 |
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
Primary Myelofibrosis (PMF)|Post-polycythemia Vera (Post-PV) Myelofibrosis|Postessential Thrombocythemia (Post-ET) Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02515630 |
| Momelotinib (CYT387) |
NCT02258607 |
Terminated |
Phase 1 |
Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase |
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT02258607 |
| Momelotinib (CYT387) |
NCT02244489 |
Terminated |
Phase 1 |
Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma |
Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02244489 |
| Momelotinib (CYT387) |
NCT02124746 |
Completed |
Phase 2 |
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia |
Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT02124746 |
| Momelotinib (CYT387) |
NCT02101268 |
Active, not recruiting |
Phase 3 |
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF |
Primary Myelofibrosis (PMF)|Post-polycythemia Vera (Post-PV)|Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) |
https://ClinicalTrials.gov/show/NCT02101268 |
| Momelotinib (CYT387) |
NCT02101021 |
Terminated |
Phase 3 |
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
Metastatic Pancreatic Ductal Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02101021 |
| Momelotinib (CYT387) |
NCT01998828 |
Terminated |
Phase 2 |
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia |
Polycythemia Vera|Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT01998828 |
| Momelotinib (CYT387) |
NCT01969838 |
Active, not recruiting |
Phase 3 |
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis |
Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01969838 |
| Momelotinib (CYT387) |
NCT04173494 |
Recruiting |
Phase 3 |
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) |
Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT04173494 |
| Momelotinib (CYT387) |
NCT02206763 |
Terminated |
Phase 1 |
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) |
EGFR Mutated EGFR TKI Naive Metastatic NSCLC |
https://ClinicalTrials.gov/show/NCT02206763 |
